|
Volumn 368, Issue 20, 2013, Pages 1931-1932
|
HCV treatment - No more room for interferonologists?
|
Author keywords
[No Author keywords available]
|
Indexed keywords
BOCEPREVIR;
PEGINTERFERON;
PEGINTERFERON ALPHA2A;
PLACEBO;
RIBAVIRIN;
SOFOSBUVIR;
TELAPREVIR;
ANEMIA;
ANTIVIRAL ACTIVITY;
ANTIVIRAL RESISTANCE;
DOSAGE SCHEDULE COMPARISON;
DRUG EFFICACY;
DRUG SAFETY;
DRUG TARGETING;
EDITORIAL;
GENOTYPE;
HEMOLYTIC ANEMIA;
HEPATITIS C;
HUMAN;
INCIDENCE;
LEUKOPENIA;
MICROBIOLOGICAL PARAMETERS;
OPEN STUDY;
PRIORITY JOURNAL;
RANDOMIZED CONTROLLED TRIAL (TOPIC);
SUSTAINED VIROLOGIC RESPONSE;
TREATMENT CONTRAINDICATION;
TREATMENT DURATION;
TREATMENT FAILURE;
TREATMENT RESPONSE;
UNSPECIFIED SIDE EFFECT;
VIRUS REPLICATION;
|
EID: 84877731714
PISSN: 00284793
EISSN: 15334406
Source Type: Journal
DOI: 10.1056/NEJMe1303818 Document Type: Editorial |
Times cited : (32)
|
References (7)
|